RxDoctor Payments DataLook up a doctor →

Ben Barnett, MD

Infectious Disease · Houston, TXNPI 1457379687

Payments from drug & device makers

$424,084in general payments, 2019–2025

Across 563 payments — averaging $753.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$260K
  • Viiv Healthcare Company$125K
  • Merck$29K
  • Theratechnologies Inc.$8K
  • GSK$975
  • Janssen Scientific Affairs, LLC$800
  • plus $286 from 7 others

What the payments were for

  • Consulting fees$70,09517%
  • Speaking & faculty fees$306,72572%
  • Travel & lodging$36,3969%
  • Food & beverage$10,8683%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$424,084 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$13,977
Medicare patients
70
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala319$1,161,863
DovatoDolutegravir Sodium/Lamivudine67$190,808
GenvoyaElviteg/Cob/Emtri/Tenof Alafen34$163,917
TrogarzoIbalizumab-Uiyk11$126,483
RukobiaFostemsavir Tromethamine12$100,035
OdefseyEmtricitab/Rilpiviri/Tenof Ala26$98,806
TivicayDolutegravir Sodium41$94,987
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$69,131
DescovyEmtricitabine/Tenofov Alafenam26$39,007
JulucaDolutegravir/Rilpivirine11$36,694
JardianceEmpagliflozin17$22,337
EntrestoSacubitril/Valsartan25$19,597
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)22$6,404
Albuterol Sulfate HfaAlbuterol Sulfate46$1,236
Atorvastatin Calcium83$701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$259,645$1,364,787379 claims
Viiv Healthcare CompanyDovato, Rukobia, Tivicay, Juluca$125,347$422,524131 claims
Theratechnologies Inc.Trogarzo$7,591$126,48311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →